# Compare Semaglutide, Tirzepatide, and Retatrutide — Peptide Mundo

> A side-by-side comparison of three Metabolic & Weight Research incretin peptides — semaglutide, tirzepatide, and retatrutide — across receptor class, most-studied application, evidence base, administration, regulatory status, and key caution.

How single, dual, and triple incretin agonism differ in mechanism, trial results, regulatory standing, and what you do and do not yet know.

## The short version

This page lines up [semaglutide](/semaglutide), [tirzepatide](/tirzepatide), and [retatrutide](/retatrutide) on the dimensions that matter most when reading incretin-class peptide research: receptor class, most-studied application, evidence base, administration route, regulatory standing, and the single most important caution for each. The headline is clean. All three are studied for metabolic regulation and weight management, and each additional receptor arm has produced greater weight loss in trials — but only semaglutide and tirzepatide are approved medicines, and retatrutide is still investigational with no Phase 3 data published. None of this is medical advice, and no human dose is recommended here.

## The comparison matrix

| Dimension | Semaglutide | Tirzepatide | Retatrutide |
| --- | --- | --- | --- |
| Peptide class | GLP-1 receptor agonist (single incretin arm) | GIP/GLP-1 dual receptor agonist ("twincretin") | GIP/GLP-1/glucagon triple receptor agonist |
| Most-studied in | Type 2 diabetes, obesity, cardiovascular outcomes, CKD, MASH | Type 2 diabetes, obesity, sleep apnea | Obesity, type 2 diabetes, metabolic liver disease (MASLD) |
| Evidence base | Large RCTs: STEP, SELECT, FLOW, SUSTAIN programs; FDA-approved [4][3][2] | Large RCTs: SURMOUNT, SURPASS programs; head-to-head vs semaglutide [1][8][9] | Phase 2 only (Phase 3 ongoing); not approved [15][16] |
| Administration studied | Once-weekly SC injection; once-daily oral tablet [5] | Once-weekly SC injection [6] | Once-weekly SC injection (Phase 2) [15] |
| Regulatory status | FDA-approved (T2D, weight management, MACE reduction, MASH) | FDA-approved (T2D, weight management, sleep apnea) | Investigational; not approved anywhere as of mid-2026 |
| Key caution | GI intolerance; weight regain after stopping; lean-mass loss [5] | GI intolerance; gallbladder disease signal; lean-mass loss [7] | Not approved; dose-dependent heart-rate increase; long-term safety unknown [15] |

## Peptide class

The three compounds span a receptor-engagement spectrum. Semaglutide targets one receptor, GLP-1R, with a C18 fatty di-acid arm enabling once-weekly dosing. Tirzepatide targets two — GLP-1R and GIPR — with a C20 fatty diacid arm; the engagement is asymmetric, favoring GIPR, and its GLP-1R signaling is biased toward cAMP over beta-arrestin [10]. Retatrutide targets all three incretin/glucagon receptors (GLP-1R, GIPR, GCGR) in a single 39-amino-acid molecule; cryo-EM work shows distinct structural conformations at each receptor, with potency approximately 8.9-fold above native GIP at GIPR but subphysiological at GCGR and GLP-1R [13]. The progression is not simply adding receptors: each additional target changes the mechanism of action in a qualitatively distinct way.

## Most-studied application

Semaglutide has the widest footprint by indication: type 2 diabetes, chronic weight management, cardiovascular event reduction (SELECT), kidney-disease event reduction (FLOW), and now MASH [2][3][4]. Tirzepatide's trial program centers on type 2 diabetes (SURPASS) and obesity (SURMOUNT), with the head-to-head SURMOUNT-5 providing the clearest direct comparison [1][8][9]. Retatrutide's Phase 2 trials address obesity, type 2 diabetes, and a 2024 MASLD substudy that showed 86% of participants at the highest dose reaching normal liver fat at 24 weeks [14][15][16]. All three are therefore metabolic agents; the evidence base behind each is just at very different stages.

## Evidence base

This is where the three genuinely separate. Semaglutide has the deepest and most diverse clinical evidence: multi-thousand-participant RCTs across multiple indications, years of real-world pharmacovigilance, and a comprehensive safety-review literature [2][3][4][5]. Tirzepatide builds on comparable phase 3 infrastructure and now has a head-to-head superiority trial against the semaglutide standard [1][8][9]. Retatrutide's entire evidence base is Phase 2: two pivotal 281-338-participant trials and a 98-participant substudy, all published 2023-2024, with Phase 3 not yet reported [14][15][16]. The trajectory is encouraging, but a Phase 2 signal has not been Phase 3-confirmed.

## Administration studied

All three are given as once-weekly subcutaneous injections in their pivotal trials, made possible by fatty-acid side chains that confer albumin binding and extended half-lives. Semaglutide is the only one also available as an oral formulation, but oral bioavailability is only ~0.4-1% and strict fasted administration is mandatory; administration errors substantially reduce efficacy [5]. Tirzepatide and retatrutide are injection-only in the studied and (for tirzepatide) approved forms [6][15].

## Regulatory and approval status

Semaglutide and tirzepatide are FDA-approved prescription medicines. Semaglutide holds approvals across type 2 diabetes (injectable and oral), chronic weight management, MACE reduction in established CVD, and (2025) MASH. Tirzepatide is approved for type 2 diabetes, chronic weight management, and moderate-to-severe sleep apnea. Retatrutide is not approved by any regulator as of mid-2026 — it is an investigational drug studied only under clinical-trial conditions [6][12][15]. Material described as "research-grade" retatrutide available outside trials carries no verified identity, purity, or sterility, and the FDA issued enforcement actions against vendors in 2025 [12].

## Key caution

Each compound carries a defining caveat. For semaglutide it is the combination of GI intolerance as the dominant adverse effect during dose escalation and the clinical-trial evidence that weight regain after stopping is substantial — framing this as chronic rather than curative therapy [5]. For tirzepatide it is the consistently documented gallbladder and biliary disease signal across multiple pooled analyses, a finding not fully resolved by mechanism or easily mitigated [7]. For retatrutide it is the compound's investigational status combined with a dose-dependent heart-rate elevation — driven by the glucagon receptor's cardiac chronotropic effect — whose long-term cardiovascular implications remain uncharacterized in the absence of Phase 3 outcomes data [12][15]. Reading the three together, the pattern is clear: incremental mechanistic ambition is paired with incremental uncertainty about long-term safety.

---

A peer-reviewed literature digest on incretin-class metabolic peptides — citations and context, not clinical counsel.